Note 9 - Stockholders' Equity

3 Months Ended

Mar. 31, 2022

Notes to Financial Statements

Stockholders' Equity Note Disclosure [Text Block]

9. Stockholders’ Deficit

The Company has granted options to employees and Board members to purchase shares of common stock. The following is a summary of option award activity during the three months ended March 31, 2022:

	Total Stock Options Outstanding			Weighted Average Exercise Price per Share
December 31, 2021		45,468		$	14.28
Granted		—			—
Vested		—			—
Forfeited, Canceled		(2,813	)		67.00
March 31, 2022		42,655		$	10.81

The following is a summary of outstanding stock options as of March 31, 2022:

	As of March 31, 2022
	Stock Options Outstanding		Vested Stock Options
Quantity		42,655		42,655
Weighted Average Exercise Price	$	10.81	$	10.81
Weighted Average Remaining Contractual Term (in Years)		2.50		2.50
Intrinsic Value	$	—	$	—

As of March 31, 2022, there was no total compensation cost not yet recognized related to unvested stock options.

As of March 31, 2022, there are 1,347,996 restricted stock units outstanding to employees from the old Cytocom plan.